The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announces 19 new grant awards totaling more than $16.5 million to projects that serve our mission to find a cure for Parkinson’s and improved treatments for those living with the disease today. MJFF is funding as many projects as possible, collaborating with the Parkinson’s research community … Continued
Creating innovative therapeutics for serious CNS disorders
Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
Our Motivation
Though the brain plays such a critical role in our bodies, it’s interconnections have until recently been poorly understood. Consequently, very few targeted medications have been developed to help those suffering from serious central nervous system (CNS) disorders. Significant unmet medical need persists in this area, and the field has seen little innovation in the advancement of effective therapies. More
Our Platform
We’re on the forefront of developing more effective therapeutics for CNS disorders, focusing on critical neural circuits associated with the defining symptoms of disease. More
Our Clinical Programs
We have advanced our Autism program into a Phase 1 clinical trial, with many more programs under development. More